Entering text into the input field will update the search result below

Bluebird bio reverses gains a day after FDA approval of priciest drug

Aug. 18, 2022 12:01 PM ETbluebird bio, Inc. (BLUE) StockBy: Dulan Lokuwithana, SA News Editor7 Comments

Mediterranean anemia

Hailshadow/iStock via Getty Images

  • Gene therapy company bluebird bio, Inc. (NASDAQ:BLUE) fell ~14% in the morning hours Thursday, ending week-long gains a day after the FDA approved its β-thalassemia drug Zynteglo making the treatment the priciest to date.
  • The FDA decision followed

Recommended For You

About BLUE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BLUE--
bluebird bio, Inc.